← ANALYST RATINGS · TIPRANKS
Smith & Nephew Snats (SNN): analyst forecast and price target
Analyst consensus
Hold0 Buy4 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $30.96, the highest $33.88, the lowest $29.00. The average is +6.5% from the last price of $29.06.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $29.00 → $30.00+3.4% | Buy | +3.2% | Reiterated | 07.10.26on TipRanks Oct 6 23:06 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $29.00 → $30.00+3.4% | Buy | +3.2% | Reiterated | 07.10.26on TipRanks Oct 6 23:06 | — | |
| Julien Ouaddour★★★★★★★★★★#2713 · hits 65% · avg +13.8% | Bank of America Securities | $1,150 → $29.00−97.5% | Hold | −0.2% | Reiterated | 06.10.26on TipRanks 09:45 | −0.7%next day +0.3% · 5 days +3.8% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $30.00 | Buy | +3.2% | Reiterated | 05.10.26on TipRanks Oct 4 23:07 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $28.00 | Hold | −3.6% | Reiterated | 05.10.26on TipRanks Oct 4 23:07 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $30.00 | Buy | +3.2% | Reiterated | 05.10.26on TipRanks Oct 4 23:07 | — | |
| Caitlin Roberts★★★★★★★★★★#1832 · hits 65% · avg +14.7% | Canaccord Genuity | $30.00 | Hold | +3.2% | Reiterated | 23.09.26on TipRanks 07:15 | −1.8%next day −0.4% · 5 days +1.2% | ↗ |
| Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% | BTIG | — | Hold | — | Reiterated | 21.09.26on TipRanks Sep 22 07:25 | −1.1%next day −0.7% · 5 days −1.2% | ↗ |
| Sam England★★★★★★★★★★#11152 · hits 44% · avg −3.9% | Berenberg Bank | $33.77 → $33.88+0.3% | Hold | +16.6% | Reiterated | 10.09.26on TipRanks Sep 11 09:40 | 0.0%next day −1.3% · 5 days −0.1% | ↗ |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $37.00 → $34.00−8.1% | Buy | +17.0% | Reiterated | 20.08.26on TipRanks 00:05 | — | |
| Christophe dombu★★★★★★★★★★#12153 · hits 39% · avg −11.7% | Kepler Capital | — | Hold | — | Downgrade | 04.06.26on TipRanks 04:55 | +2.7%next day +1.8% · 5 days +2.0% | ↗ |
| Lisa Bedell Clive★★★★★★★★★★#10086 · hits 42% · avg −1.6% | Bernstein | $36.20 → $31.85−12.0% | Hold | +9.6% | Reiterated | 11.05.26on TipRanks 07:40 | −3.1%next day +3.5% · 5 days +4.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Smith & Nephew Snats
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 06.10.26: target $26.14 at a price of $26.92 (−2.9%); now: $30.96 at $29.06 (+6.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 6 | 7 | 7 | 8 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 23.02.27 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.21 (from $0.94 to $1.32). Last quarter: $0.43.
Sales
Next quarter’s sales estimate — $3.3B (from $3.3B to $3.3B). Last quarter: $3.1B.
Best top-analyst consensus in the sector · Healthcare
About Smith & Nephew Snats
- CEO: Deepak S. Nath
- Employees: 18,362
- Building 5 Croxley Park Hatters Lane, Watford, HRT, WD18 8YE, GB
- www.smith-nephew.com
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Data from the stock’s TipRanks forecast page, read 142 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗